Beigene, Ltd. (NASDAQ:ONC) CEO John Oyler Sells 5,127 Shares of Stock

Beigene, Ltd. (NASDAQ:ONC) CEO John Oyler sold 5,127 shares of Beigene stock in a transaction dated Friday, June 6th. The stock was sold at an average price of $252.77, for a total transaction of $1,295,951.79. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Beigene Price Performance

ONC stock opened at $263.42 on Wednesday. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.93 and a quick ratio of 1.72. The company’s 50-day moving average price is $238.58. Beigene, Ltd. has a 52-week low of $141.31 and a 52-week high of $287.88. The company has a market capitalization of $31.18 billion, a PE ratio of -31.97, a price-to-earnings-growth ratio of 7.73 and a beta of 0.30.

Beigene (NASDAQ:ONC) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $1.22 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.71) by $1.93. The firm had revenue of $1.12 billion during the quarter, compared to analyst estimates of $1.12 billion. Beigene had a negative net margin of 25.94% and a negative return on equity of 25.12%. Equities analysts expect that Beigene, Ltd. will post -5.82 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on ONC shares. Guggenheim boosted their target price on shares of Beigene from $348.00 to $350.00 and gave the company a “buy” rating in a report on Thursday, May 8th. Bank of America upgraded shares of Beigene from a “neutral” rating to a “buy” rating and raised their price target for the stock from $207.00 to $320.00 in a research report on Monday, March 3rd. Sanford C. Bernstein set a $259.00 price objective on shares of Beigene in a report on Thursday, March 13th. TD Securities reissued a “buy” rating and set a $334.00 target price on shares of Beigene in a report on Thursday, April 24th. Finally, Wall Street Zen raised Beigene from a “hold” rating to a “buy” rating in a report on Thursday, May 22nd. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $319.00.

Beigene Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.